Navigation Links
Odyssey Thera to Participate in Expanded EPA Initiative
Date:12/6/2010

SAN RAMON, Calif., Dec. 6, 2010 /PRNewswire/ -- The United States Environmental Protection Agency (EPA) announced today a new phase of toxicity screening, in which 1,000 chemicals will be screened as part of EPA's ToxCast initiative. Odyssey Thera's participation in this program, first announced earlier this year, involves the application of extensive and diverse proprietary assay and screening technologies. "The Odyssey team is very pleased with our contributions to ToxCast to date, and we're excited to see this program accelerating," said Dr. Jane E. Lamerdin, Executive Director of R&D at Odyssey Thera, "ToxCast represents an ideal application of our validated chemical analysis strategies."

The chemicals will be assessed for potential toxicity to people and the environment. ToxCast is designed to determine how chemical exposures impact human biological processes and how the chemicals most likely lead to health effects. When fully implemented, ToxCast will be able to screen thousands of chemicals in fast, cost-effective tests that are relevant to human health. The chemicals being tested are found in industrial and consumer products, food additives and drugs that never made it to the market.

The full news release can be found at: http://yosemite.epa.gov/opa/admpress.nsf/d0cf6618525a9efb85257359003fb69d/73ec2518e34bc93d852577eb0060dd7c!OpenDocument. More information on ToxCast and the list of chemicals can be found at http://www.epa.gov/comptox.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a privately held drug discovery technology company focused on improving the success rate of new therapeutic development. Odyssey Thera's technology measures disease–relevant pathway activity within living human cells. Odyssey is leveraging its proprietary drug discovery and development platform for internal programs and for premier pharmaceutical and biotechnology company partners. Patents owned by Odyssey also cover the use of the technology in live animals, plants and for diagnostic and bioprocess applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
2. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
3. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
4. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
5. Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy
6. Halozyme Therapeutics Realigns Management
7. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
8. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
9. SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
10. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
11. Neuro Kinetics Receives HHS Therapeutic Discovery Grant to Further Research Into Early Diagnosis of Sports Concussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... -- Following an initial analysis, the Senior Care ... Drug Administration,s (FDA,s) final regulatory guidance regarding the ... and Outsourcing Facilities." In its final guidance, the ... which would have put patients at risk and ... (LTC) pharmacies.  The agency also ...
(Date:1/17/2017)... 2017   Anesthesia Business Consultants (ABC), ... for the anesthesia and pain management specialty, discusses ... "clinical conundrum" (as described recently in Anesthesiology News) ... think carefully before recommending medical marijuana for their ... National Academies of Sciences, Engineering and Medicine, " ...
(Date:1/17/2017)... -- Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ), ... and pathology services for evaluating risks of cancer, announced ... 13, 2017 from the NASDAQ Listing Qualifications notifying the ... of the NASDAQ Stock Market to maintain a minimum ... The letter noted that for the last 10 days ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... ... 17, 2017 , ... Kevin Harrington (one of the original Sharks from mega-hit ... regarding the topic of Beauty and Personal Care. , Everyone makes ... way to commit to these changes than beginning with personal care and beauty products? ...
(Date:1/17/2017)... Houston, TX (PRWEB) , ... January 17, 2017 , ... ... they have earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. ... been named part of this elite group of providers. , Produced by Zeltiq, ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... A prescription ... winners of the fourth Cradle to Cradle Product Design Challenge , the ... in a series of six circular design challenges scheduled to run through early 2018. ...
(Date:1/17/2017)... ... ... SC&H Group, a leading audit, tax, and consulting firm, announced that Chris ... practice . Rossi is the third technology consulting leader to join SC&H Group’s IT ... the practice continues to expand.     , Bringing more than 25 years of business consulting ...
Breaking Medicine News(10 mins):